Sold as Fluorine F-18, Sodium Fluoride F 18. Every FDA application for this active ingredient: 2 branded and 24 generic.
As of Nov 22, 2026, FDA lists 26 applications for Sodium fluoride F-18 (sold as Fluorine F-18, Sodium Fluoride F 18), first approved Feb 24, 1972, with 0 new uses approved and 0 published complete response letters.
| Feb 24, 1972 | Fluorine F-18NDA 17042 · New molecular entity | GE Healthcare | 0 | Discontinued |
| Jan 26, 2011 | Sodium Fluoride F 18NDA 22494 · New formulation or manufacturer | NIH NCI DCTD | 0 | Discontinued |
| Dec 26, 2012 | Sodium Fluoride F-18ANDA 203544 | SOFIE | 0 | Discontinued |
| Jun 28, 2013 | Sodium Fluoride F-18ANDA 203605 | MCPRF | 0 | Marketed |
| Dec 23, 2013 | Sodium Fluoride F-18ANDA 203247 | Univ Tx Md Anderson | 0 | Discontinued |
| Mar 13, 2014 | Sodium Fluoride F-18ANDA 204437 | UCSF Radiopharmacy | 0 | Discontinued |
| Sep 22, 2014 | Sodium Fluoride F-18ANDA 204315 | Shertech Labs | 0 | Discontinued |
| Oct 21, 2014 | Sodium Fluoride F-18ANDA 204464 | Decatur | 0 | Discontinued |
| Oct 29, 2014 | Sodium Fluoride F-18ANDA 204541 | Essential Isotopes | 0 | Discontinued |
| Nov 19, 2014 | Sodium Fluoride F-18ANDA 204328 | Feinstein Institutes for Medical Research | 0 | Marketed |
| Nov 28, 2014 | Sodium Fluoride F-18ANDA 204513 | NCM USA Bronx | 0 | Marketed |
| Jan 9, 2015 | Sodium Fluoride F-18ANDA 204351 | Biomedcl Res Fdn | 0 | Marketed |
| Feb 27, 2015 | Sodium Fluoride F-18ANDA 204542 | Precision Nuclear | 0 | Marketed |
| Apr 20, 2015 | Sodium Fluoride F-18ANDA 204497 | Univ Utah Cyclotron | 0 | Marketed |
| Apr 22, 2015 | Sodium Fluoride F-18ANDA 203912 | Nukemed | 0 | Discontinued |
| Jul 21, 2015 | Sodium Fluoride F-18ANDA 204517 | MIPS CRF | 0 | Marketed |
| Jul 29, 2015 | Sodium Fluoride F-18ANDA 204530 | Hot Shots NM | 0 | Discontinued |
| Jul 30, 2015 | Sodium Fluoride F-18ANDA 203780 | Cardinal Health 414 | 0 | Marketed |
| Aug 18, 2015 | Sodium Fluoride F-18ANDA 203592 | SOFIE | 0 | Marketed |
| Sep 28, 2015 | Sodium Fluoride F-18ANDA 203890 | PETNET Solutions | 0 | Marketed |
| Oct 19, 2015 | Sodium Fluoride F-18ANDA 203777 | 3D Imaging Drug | 1 | Marketed |
| Oct 23, 2015 | Sodium Fluoride F-18ANDA 203968 | Jubilant Draximage | 0 | Marketed |
| Nov 17, 2015 | Sodium Fluoride F-18ANDA 204440 | Midwest Medical | 0 | Marketed |
| Nov 17, 2015 | Sodium Fluoride F-18ANDA 204462 | UIHC PET Imaging | 0 | Discontinued |
| May 19, 2016 | Sodium Fluoride F-18ANDA 203936 | Kreitchman PET Center | 0 | Marketed |
| Dec 6, 2022 | Sodium Fluoride F-18ANDA 216126 | BAMF | 0 | Marketed |
| F-18 Sodium Fluoride PET/CT-Guided Pain Palliation in Chronic Plantar Fasciitis: A Comparative Study of ¹⁷⁷Lutetium-Corticosteroid-Local Anaesthetic Injection vs Corticosteroid-Local Anaesthetic InjectionPlantar Fascitis, Chronic Heel Pain · Post Graduate Institute of Medical Education and Research, Chandigarh | Not applicable | Recruiting | Oct 30, 2026 |
| PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck CancerClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Emory University | Early phase 1 | Recruiting | Apr 7, 2025 |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerHereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma · National Cancer Institute (NCI) | Phase 2 | Recruiting | Jul 29, 2021 |
| VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial CancerMetastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma · Mayo Clinic | Phase 1 | Active, not recruiting | Apr 19, 2017 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA